Mr. Pyszczymuka is a proven commercial leader with extensive experience in pharmaceutical sales, market access, and revenue ...

The kits include two Narcan nasal spray devices with instructions for the proper administration and steps to be taken in the ...

The neffyinSchools program from ARS Pharma will provide eligible public and private K-12 schools in the United States with ...

On Wednesday, the House Labor, Health and Social Services Committee voted unanimously in favor of Senate File 74, “ Immunity ...

The FDA reviews drug approval decisions that are expected in March 2025. The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled ...

Many recalls come as a result of product mislabeling, safety issues or contamination. Here are five recalls in particular ...

Compared with placebo, zavegepant nasal spray yielded sustained relief of acute pain and function in migraine.

Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...

Milestone Pharmaceuticals (MIST) announced that it has received Notice of Allowance from the United States Patent and Trademark Office, or ...

Researchers at Texas A&M University College of Medicine have developed a new therapy that may slow the progression of ...